In:
Combinatorial Chemistry & High Throughput Screening, Bentham Science Publishers Ltd., Vol. 26, No. 13 ( 2023-11), p. 2380-2392
Abstract:
This study aimed to evaluate the underlying pharmacological mechanisms of
Apatinib anti-bladder cancer via network pharmacology and experimental verification. Methods: Network pharmacology was used to screen the possible signaling pathways of Apatinib
in bladder cancer, and the most likely pathway was selected for in vitro validation. CCK-8 and colony formation assay were used to detect the effect of Apatinib on the proliferation of bladder cancer
cells. Hoechst staining and flow cytometry detected apoptosis of bladder cancer cells induced by Apatinib. Western blot was performed to distinguish the effect of Apatinib on the expression
levels of key targets. Results: Apatinib can affect many signaling pathways and the correlation of the PI3K-AKT
signaling pathway was the greatest. In vitro experiments showed that Apatinib could inhibit bladder cancer cell proliferation, induce apoptosis, and up-regulate the expression of apoptosisrelated
proteins Cleaved-PARP and down-regulate the expression of Bcl-2. Furthermore, Apatinib could decrease the protein expression of VEGFR2, P-VEGFR2, P-PI3K and P-AKT. Conclusions: Apatinib could promote apoptosis of bladder cancer cells by inhibiting the VEGFR2-
PI3K-AKT signaling pathway.
Type of Medium:
Online Resource
ISSN:
1386-2073
DOI:
10.2174/1386207326666230228101008
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2023
SSG:
15,3
Permalink